Ir al contenido principal
← Toda la financiación verificada
Nivel AUS

Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)

National Institutes of Health

Inicia sesión y completa tu Funding Passport para ver si calificas — un veredicto transparente basado en reglas, no una caja negra.

Iniciar sesión

Sobre esta oportunidad

The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The data thus far suggests that these agents may increase the risk of some, while decreasing the risk of other obesity related cancers.

Documentos requeridos

La fuente oficial no indica documentos específicos aquí — confirme los requisitos antes de postular.

Fuente y trazabilidad de verificación

Primera obtención
20 de noviembre de 2026
Última verificación
20 de noviembre de 2026
Huella del contenido
fd4a340e68554f8d…